RSS   Newsletter   Contact   Advertise with us
Post Online Media

Adaptimmune strengthens board with new appointment

AdaptimmuneAdaptimmune Therapeutics plc, a clinical stage biopharmaceutical company, appoints Barbara Duncan to its board of directors as an independent non-executive director effective from June 23, 2016.
Article continues below

READ MORE Trillium Therapeutics appoints Helen Tayton-Martin to board

Ms. Duncan will also serve as a member of the Audit Committee. Ms. Duncan has over 15 years of experience in the life sciences industry.

She has served as Chief Financial Officer and Treasurer at Intercept Pharmaceuticals, Inc. since May 2009. Ms. Duncan currently serves as a director for public company, Medgenics, Inc. and for privately held Edgemont Pharmaceuticals, LLC.

She previously served as Chief Financial Officer and then Chief Executive Officer at DOV Pharmaceuticals, Inc. from 2001 to 2009.

Before that, she served as Vice President of Corporate Finance - Global Healthcare at Lehman Brothers Inc. and as Director of Corporate Finance at SBC Warburg Dillon Read Inc.

Ms. Duncan holds a Master of Business Administration from the Wharton School of the University of Pennsylvania and a Bachelor of Business Administration from Louisiana State University.

 LATEST MOVES FROM Pennsylvania 


We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy